Fast and accurate diagnoses are critical for improving the chances of full recovery. However, the current standard of care takes days, leading to suboptimal delays. Melio, a LongeVC’s portfolio company, has developed a diagnostic platform for infectious diseases that can identify pathogens in a matter of hours. Their progress is promising in the worldwide fight against antibiotic resistance.
In a recent article, Melio CEO Mridu Sinha, Ph.D. shares more about the company's mission and vision, and how becoming a member of Fogarty Innovation's Company Accelerator Program (CAP) has been a game-changer for her and for Melio.
You can read more about it here.
Moreover, Melio co-founder and scientific advisor Stephanie Fraley shared more about their technology for KPBS Evening Edition. You can watch it here (starting at 12:30).
In a recent article, Melio CEO Mridu Sinha, Ph.D. shares more about the company's mission and vision, and how becoming a member of Fogarty Innovation's Company Accelerator Program (CAP) has been a game-changer for her and for Melio.
You can read more about it here.
Moreover, Melio co-founder and scientific advisor Stephanie Fraley shared more about their technology for KPBS Evening Edition. You can watch it here (starting at 12:30).